CEOInterviews.AI
Start App
Get an email when Robert Langer gives a new interview
One email per new interview. Unsubscribe in one click.
Robert Langer
Institute Professor, MIT

Portals to Excellence and Impact Presentation and Fireside Chat with Dr. Bob Langer

📅 May 04, 2026 HMS OCCE 85 MIN 31 VIEWS 94 SEGMENTS · 9 SPEAKERS
April 15, 2026 "The Edison of Medicine: Robert Langer's Quest to Solve Global Health Challenges Using Biotechnology" Speaker: Robert Langer, ScD, David H. Koch Institute Professor, MIT Robert Langer is one of 9 Institute Professors at MIT; being an Institute Professor is MIT’s highest honor. His articles have been cited over 467,000 times; his h-index of 335 is the highest of any engineer in history. His patents have licensed or sublicensed to over 400 companies; he is a cofounder of many companies including Moderna. He holds 45 honorary doctorates and has received over 220 awards, includin...

Questions asked in this interview

12
  1. 35:11What is it that enabled you to keep pursuing?
  2. 38:01Can you talk a little bit about this journey?
  3. 47:03Are there other big areas that you think are of change in science?
  4. 48:59Can you talk a little bit about your thoughts on how we bring individuals into science or who's left out, who's included, and is it important for us to be thinking about that?
  5. 52:14I love these moments of, do I say anything? Do I ask anything?
  6. 53:34And I was just wondering if you could comment on that retention time with the pills and the oral?
  7. 58:36What's the culture in the environment in which you learn?
  8. 1:00:53Okay, but how do you make connections is what I heard you say from here. Others?
  9. 1:01:55What's the thing that you're most proud of?
  10. 1:08:57My question was how do you define success and outside of the lab, what things kept you going in the hardest times?
  11. 1:12:18Do you have any suggestions on how your thought process has changed in investments?
  12. 1:18:53With all the pace and the breadth of developments today combined with the advancements of AI and foundational biology and technology, are there some fields that you expect to have the maximum impact in the next 25 years or so?
Joan Reede 0:00 ↗
Good afternoon. We're going to get started with today's program, and I want to welcome all of you. My name is Dr. Joan Reede. I'm Dean for Culture and Community Engagement here at Harvard Medical School. And thank you for joining us today in our "Portals to Excellence and Impact" presentation and fireside chat.
Just some housekeeping tips before we get started. Please note that this event is being recorded, and if you're attending this event in person and you don't want to be filmed, stay out of the camera, just saying, okay. And position yourself sort of to the side or someplace where you won't be included in that. Live closed captioning is available on Zoom. And after the conversation, we'll invite questions in person and through the Zoom, through the Q&A function. And the recording is going to be available on our site Office for Culture and Community Engagement in a few weeks.
Before we begin, I just want to go over what we call the rules of the road here as we join together in dialogue and conversation. And it's really about how we respect each other. It's remembering that no one's perfect. We are all here. We are all learning. Invite others into your conversations as you sit at these different tables. Words that you use do matter. Words can heal, but words can always hurt. So choose your words thoughtfully. Be respectful. We are here in conversation about perspective, not the person or people. And part of understanding is putting yourself in others' place and this concept of evidence and opinion. And each one is extremely important, but they are not interchangeable. So remember that and consider alternatives. We believe in free speech, but sometimes free speech can be uncomfortable. So we respect ourselves and others through this.
The new "Portals to Excellence and Impact" framework seeks to connect, convene and catalyze physicians and scientists in the greater Boston area who are committed to fostering excellence in health and healthcare, and to nucleating ideas within the academy, healthcare and industry. Today's forum, its presentation and fireside chat, provide an environment to enrich the research that we do in support of exploration, idea generation and early-stage thinking about new and emerging research, but research that crosses boundaries and crosses disciplines and organizational units. We hope to cultivate intellectual communities and shared inquiry among the participants and stakeholders.
Today we are honored to be joined by Dr. Robert Langer, one of the most influential scientists and inventors of our time. The title of his presentation, "The Edison of Medicine: Robert Langer's Quest to Solve Global Health Challenges Using Biotechnology," really sets the stage for this launch of portals. Robert Langer is one of nine Institute Professors at MIT, with Institute Professor being one of MIT's highest honors. His articles have been cited over 467,000 times, and his h-index, if we had more time, I'd say guess what it is, but I'm just going to put it out there. It's 335, and it's the highest of any engineer in history. He's widely regarded as the father of controlled drug delivery and tissue engineering. And his groundbreaking work in biocompatible polymers and lipid nanoparticles helped to make mRNA vaccines possible, touching the lives of so many across the world. Dr. Langer's patents have been licensed or sublicensed to over 400 companies. He is co-founder of many companies, including Moderna. He holds 45 honorary doctorates, received more than 200 awards, including both United States National Medal of Science and Technology and Innovation, and one of only three living individuals who've received both honors, and he's been elected to the National Academy of Medicine, Engineering, Sciences, Inventors.
I want to say, before we start, and before I turn this over to him, he has had so many accomplishments, but in all my interactions, I've found him to be open and supportive. And supportive of not just the kind of work that I do, but supportive of those who are coming up in the sciences. From your stage here with your postdocs and early career faculty members and others, but also reaching back to people who are much younger, and really understanding the need for pipeline and pathways into the sciences, but to hold people up. And the other part, I want to just say here now as I've come to know him better, we share the, I'd say, the honor and privilege of having known some greats. And here I'm talking about Judah Folkman, that in our conversation for me, it was this understanding that we both were graced with knowing a great individual. I'm now going to turn this over to Dr. Langer for his presentation. We'll follow with a fireside chat and then really open it up for conversation with all of you. Thank you.
Robert Langer 5:52 ↗
Thank you, Joan. Thank you. Well, thank you very much. I'm kind of embarrassed to hear all that, but it's such a pleasure to see some old friends. And anyhow, what I thought I'd try to do is start out and tell you a little bit about how I got started and, you know, go into even some of the things we're doing on global health at the end. So my background, like, I got a doctorate in chemical engineering in 1974. And that year, you know, there was a supposedly big gas shortage. And you actually, for those of you who are old enough, if you had a car, you had to wait in line about two hours to get your tank filled. But the consequence of that is, if you were a chemical engineer, you got a lot of job offers. And so almost all my friends, they went to work for oil companies, and I thought I'd do the same. I got actually 20 job offers, four from Exxon alone, and I wasn't that good by any means, but they just had so many openings, but I really wasn't that excited about it. I remember flying back to Boston one night from one of the Exxons in Texas, and, you know, they had already told me that if you could just increase the yield of some chemical by like 0.1%, how great that would be, and it would be worth billions of dollars. But I just thought to myself, I didn't want to spend my life doing that. And it was a very useful experience to know what you don't want to do. And so I started thinking about other things I might do. And one day I saw an ad to be an assistant professor to develop a new chemistry curriculum at City College of New York to develop new chemistry curriculum. And I was very excited about that. And the reason is, when I was supposed to be doing my PhD thesis, I actually spent a lot of my time helping start a school for low-income kids in Cambridge. And I got very involved in developing new chemistry curriculum and math curriculum to try to make them interesting and relevant. So I wrote them a letter applying for a job, but City College didn't write me back. But I liked that idea. So I found all the other places that might have openings to do something like that, about 40 colleges. And I wrote them. And I don't think any wrote me back, you know, I guess I wasn't in the right box, the chemistry education box. So that wasn't going so well. So I thought, what other way could I use my chemical engineering background to help people? And I thought about medicine. So I wrote to a lot of hospitals and medical schools, and they didn't write me back either, but then one day I was walking into the lab, I was at MIT, and one of the older scientists said, Bobby, there's a surgeon in Boston named Judah Folkman. And he said, sometimes he hires unusual people. He thought very highly of Dr. Folkman. I won't say what he thought about me. But anyhow, I wrote to Dr. Folkman and he was kind enough to offer me a job. And I'll just go to the slides.
This was from The New York Times, I think in 1971. And his idea was that blood vessels were critical to the tumor growing and of course, and even, and to metastasis and so forth. And that it was chemically mediated by something called tumor angiogenesis factor. And I thought when I heard this, it sounded incredible. You know, he thought if you could stop that, it might be a new way to treat cancer. And what I didn't know, and it's interesting, and for those of you that followed Dr. Folkman's career, he was widely criticized for this. I mean, people said that this was wrong. It was impossible. I thought it was terrific and that he, you know, even that you could think about something like that. So it was by far the lowest paying job that I got. But it was, I thought, terrific. And I went to work at Children's. I was the only engineer there. And so what was key to try, what he wanted me to do was to see if we could actually prove that he was right, that there would be substances that could stop blood vessels from growing, and of course it was very hard to study. So the first key was developing a bioassay. And that's not so easy because there's always background blood vessels wherever you go, but a couple places are not. One is the chick chorioallantoic membrane, which has very few, and then there's the cornea, which has none. So one of the things that we thought about was maybe we could put a tumor in these sites. For the biologists, we were often using a V2 carcinoma, though we used others. And then we wanted to have a tiny delivery system that you could put in these places like a microparticle or a nanoparticle. And what we wanted it to be is something that could deliver large molecules. We were looking at different large molecules, large molecules are proteins, glycoproteins, DNA, RNA, things like that. So that had never been done before. In fact, the idea of an advanced drug delivery system, this was 52 years ago, was pretty much non-existent except for one company in the United States. And again, for those of you that are old enough, that company was called ALZA. And they would ultimately come out and make transdermal patches and things like this. But in 1974, none of this existed, but they were doing research on it. They had some very good scientists, and they had an incredibly good board. And they asked Dr. Folkman to be on it. They asked some Nobel Prize winners in chemistry to be on it. And Dr. Folkman went out there, and he asked them, could they help? And what they told him was that, no, you know, that the idea of delivering a large molecule, that would be impossible because it's like, you know, walking through a wall, they just, I mean, you could make holes in it, but then it's out instantaneously. So the basic idea was that would be nonexistent, but if we were going to address the angiogenesis problem, we had to solve this problem. So I spent several years working in the laboratory, experimenting with different materials, different designs. I actually found over 200 different ways to get this to not work. But eventually we were able to make little microparticles and nanoparticles, and we showed, actually in Nature. This was a paper that Dr. Folkman and I wrote, and I'll come back to this later too, but you could actually with certain technologies we created, you could actually deliver large molecules. It's also the very first time that nucleic acids like DNA or RNA had been delivered. So I want to go back to three months before that paper came out. So I got asked, really for the first time in my life to give a talk at a major scientific meeting. It was in Michigan. I practiced this talk for weeks, and I was 27 then. I'm 77 now. But I still remember this. I gave the talk and I was super nervous, but at the end of it, I thought I did okay. I didn't forget that much of what I was going to say. I didn't stammer too much. And so I thought when I was done, you know, giving this lecture to this older audience of really very distinguished chemists and engineers, I thought that they being nice people would encourage me, this young guy. And when I got done, I stepped off the podium and a whole bunch of them came up to me and they said, we don't believe anything you just said. And in fact, what they said was, again, the molecules were too big. They also said the solvents we were using, like methylene chloride and ethanol, would destroy whatever we put in. So that was not very good. And then things kind of went downhill from there, if that were possible. I tried to get research grants. My first nine were rejected, and I got statements coming back that Dr. Langer, you know, again, I don't know how these study sections probably don't exist anymore, but then you'd send it to Pathology B Study Section. I still remember them. And they get reviews back. Well, like Dr. Langer is an engineer. He knows nothing about biology and even less about oncology, which I thought I knew something about math, and I didn't think that was possible. But at any rate, I didn't get the grants for a while. And then, you know, I love being a postdoc at Children's Hospital, but a lot of my friends would say to me, probably I shouldn't do that forever. So I started applying for faculty positions again. And since I'm a chemical engineer, the obvious places I applied to were chemical engineering departments, and no chemical engineering department in the country would hire me. I got some interviews, but no place. They thought that trying to do bio stuff, you know, didn't make any sense that I should be doing energy or other kinds of things like that. So I didn't get any jobs. But Dr. Folkman introduced me to Nevin Scrimshaw, who was the head of the nutrition department at MIT. And Dr. Scrimshaw, he was a visionary guy, and he was also what I call a benevolent dictator kind of department head. I mean that in a good way, for me at least, 'cause he liked me, so he offered me a job as an assistant professor, but he didn't ask anybody else in the department what they thought, which would've been okay except for one thing, which was that the year after I joined the department, he left. So, I'll back up. So a lot of the senior faculty decided to give me advice. And their advice was I should leave too. And to just tell you a story. This is also true. You know, and this is in 1979, Mike Marletta was also in that department. Mike later on became head of Berkeley's chemistry department, actually the head of Scripps as well as a member of the National Academy of Sciences. And he now is a good friend. So about 15 years ago, I got some award and he gave a speech. I just excerpted this one part. And basically what he wrote, which I sort of remember too, he said, one evening he went to a faculty dinner at a Chinese restaurant with me and some senior MIT professors. He said, a senior scientist sat quizzing us while smoking a cigar. He said, when the older scientists heard my concepts for drug delivery, this was 1979, he is referring to, he said he blew a cloud of smoke in my face and said, you better start looking for another job. So this was my introduction to my first few years at MIT, which wasn't so good either. So what would happen, you know, which is just to go over a few things. So we had developed, like I said, with Dr. Folkman, these delivery systems. So we could actually, for the first time, look at whether we could find anything that could stop blood vessels from growing. And so what we did is, this is a paper he and I wrote in Science in 1976. And what you see, this is just one of many papers. We had graphs and everything, but what you can see is with an inhibitor, without an inhibitor, if you go to your left, what you see is these sheets of blood vessels. But when you put at least this one extract, it's not purified. But what you see, it was pretty remarkable. The blood vessels are lower, they're sparser, and they even avoid the tumor. So this really did show, and it was quite, we probably, I always say we had a lot of controls, 'cause I kept isolating different things that didn't work. And probably over a hundred. We probably did over 2,000 eyes. And so it shows that you can find these things and it shows that you can stop blood vessels. We continued and even showed that there were ways to infuse them in. And that was a later paper in PNAS and so forth. But at least it started to show for the first time that blood vessel inhibitors and Dr. Folkman's theory, you know, was correct. So you all probably know medicine's pretty slow in terms of going from doing research to clinical work. And it takes enormous amounts of money. What happened after our paper, like I said, this was a '76 paper. It took 28 years from this paper before the first blood vessel inhibitors were approved by FDA. And that was because of really outstanding work at Genentech by Napoleone Ferrara and others, and many other companies. But building on some of the early work that we'd done, and what you see starting 28 years later, going to now as many angiogenesis inhibitors got approved, Avastin is one of the most widely used biotech drugs in history. I think it's the number two bestselling biotech drug of all time. Even, I think, at 2024 it was number four. But there's all kinds of these that have been approved by FDA. Nature, the journal, estimates half a billion people will be treated by these. And they're really not only, you know, widely used in different cancer treatments, but they're pretty much the only drugs that are used to prevent diseases of blindness in the back of the eye, like diabetic retinopathy and macular degeneration. But I want to go back again now that's even taking you to today. But I want to go back to the seventies again. When Dr. Folkman and I did this work, and one of the things Dr. Folkman said to me, he says, well, we should file a patent. So we did. But that might seem quite common today, especially if people look at what I've tried to do, but, which I'll get to. But then it wasn't common at all. And Children's Hospital never had a patent at that time. So we filed a patent for the first time. Five years in a row, it got rejected. And I remember they had a guy, Al Brazzini, who was head of the tech transfer office, and he came to see me one day after five years of rejection. He said, Bob, you are wasting so much money. He said, you've gotten rejected five times the patent office, you should just quit. The patent office is never going to allow it. I said, but I don't like to quit, you know? So I started to think, how could we convince the patent examiner to allow this patent legally, of course. And science really wasn't working. But I told you in the beginning, when I first started doing this, everybody told me it was impossible. It would never work. I wonder maybe somebody wrote that down. So in 1982, this was after five years of rejection. You can do what's called a science citation search. Look at your Nature paper in '76, see who cited it and what they said, and I found, I had no idea this was written, but this was from five of the top material scientists in the world, and they wrote it in 1979. I'll just read this to you. And there were other articles too, but I mean, everybody was super skeptical that you could ever do this. But here's what they're saying. Generally, the agent to be released is a relatively small molecule with a molecular weight no larger than a few hundred. One wouldn't expect that macromolecules could be released by such a technique because of their extremely small permeation rates. However, Folkman and I have reported some surprising results that clearly demonstrate the opposite. So I realized that word surprising that the examiner that might, you know, make the examiner allow it certainly doesn't seem obvious if it's surprising. And so Dr. Brazzini flew to Washington, showed him the quote, and the examiner says, well, I will allow this patent if Dr. Langer can get written affidavits from each of these five people that they really wrote that. So I was a young professor then, and I wrote them, and they were all nice enough to write me back that they really wrote it. And we got this super broad patent. And, you know, and I'd been working on this for about 10 years. And like I said, I always had this dream that something I did, you know, might help people. And, you know, but it wasn't like companies kept calling and saying they wanted to do anything with it. I mean, people started citing the work, but I wanted it to lead to products that would help people. But in 1983, '84, I got calls from a couple multi-billion dollar companies and they said, gee, we read about your work. Could you consult for us? I mentioned the patent, said, well, we want to license the patent. We'll give you a consulting fee. You know, I had a Ford Pinto at the time, and it would give you a consulting fee. And most importantly to me, they were going to develop this and make products. And I thought this was great. And, but what happened was after a year or two, they both gave up. So that was very discouraging to me. And then Alex Klibanov, one of my good friends, said to me one day, said, Bob, we should start our own company. So with four of my students and Alex, we started this little company called Enzytech. Later it merged with Alkermes. We kept starting companies. And we kept writing patents. And to make a long story short, that's led to all kinds of products shown here. They're used by hundreds of millions of people today. They lead to new cancer treatments like Lupron Depot, drug-eluting stents, which Elazer Edelman, who was one of my students, did a lot in Boston Scientific, but also, I mean, new ways of treating opioid addiction, they're not limited to medicine. It's actually helped permit this whole area of aquaculture, which is now a quarter of a trillion dollar industry. But these are just pictures of some of the products. And, you know, they're used to all over the world. Also, I actually, what I should have also done since... Is it here? Two of the more recent ones that have been important. I was on the founding scientific advisory board of Alnylam. So we worked closely with them on Onpattro, which was the first siRNA drug. And by the way, you need, just to be clear, if you didn't have the delivery system, these drugs would be destroyed. You try to give siRNA, well, now there's ways maybe to stabilize it, or proteins or mRNA. That's probably the best example, right? If you tried to just inject messenger RNA into a patient, I mean, it would do nothing, but if you put it in a nanoparticle. And the Moderna vial, which was another company I helped start, is there too on the bottom. So it led to products that would, you know, I guess different associations have said to help several billion people. And then just to go back, I'm not doing such a good job with the clicker. So a lot of places, you know, I mentioned how, at least when I started, everybody thought this was never going to work. But, you know, now people cite that paper as really raising the possibility of all these kinds of things, using DNA or RNA as a drug. This is just two articles many in Nature that are fairly recent. The other big area that I spent a lot of time on also starting at Children's Hospital was with Jay Vacanti. And Jay, one day, actually I met him when I was a postdoc and he was, you know, was doing a fellowship and later would become head of the liver transplant program. And he one day asked me, he said, could we make a new liver? And we started talking about coming up with three-dimensional scaffolds. Also, this would get ridiculed too by the study sections. And, but at any rate, could you make tissues and organs from scratch? And we worked on it. We actually had created an interesting way to raise money. We actually started a virtual company in the 1980s 'cause we couldn't get federal funding 'cause they said this would be impossible. But that's also led to all kinds of things. Skin for burn victims, which you can see on the upper right, new blood vessels, which are, now, it's in the middle. One of my fellows, Laura Niklason, who became a professor at Yale and started a company, did that. That's now approved by FDA too. But there's all kinds of things that are up there, you know, new vocal chords we've worked on with Steve Zeitels, who's a professor. He's Julie Andrews' surgeon, that's Julie Andrews up there. But there's, not only can you start to make all these different tissues and organs, you can also start thinking about making them in vitro, which could tremendously accelerate drug testing. I mean, just a very recent example, Li-Huei Tsai, who's at the Picower Institute, asked me about five or six years ago about writing a grant to make a brain on a chip. And Alice Stanton was a postdoc with me, and she actually did that. There's a little picture. There's a big paper in PNAS a couple months ago. And Mass General has a new Neurology Institute, and she became the first faculty member they hired there. But you could start looking at this to do, literally, rather than experiments on people. Those are of course not very easy to do if you're doing, you know, things on the brain, but you could make Alzheimer's, you know, personalized brains for ALS and so forth. And so she's looking at that. So another thing that I've been involved in doing, this now goes back to 2012. You know, I never thought at 77 I'd still be doing, you know, we have a big lab and I never thought that would necessarily be my goal. But I had a visitor in 2012, and he was a software entrepreneur, but he and his wife, they were very interested in trying to solve health problems in the developing world. And here's a picture of me in my office with the software entrepreneur, which is Bill Gates. And so some of the things that we've done, I'm just going to go over this briefly, but we've worked with the Gates Foundation for the last 14 years. And I think because we've taken, well, I'll just go over some of the ideas. One is in nutrition, more than 2 billion people suffer from micronutrient deficiencies. And so one of the things that they were very interested in is, you know, you might think you could just give them vitamin pills or stuff like that, but the, people don't do that. I mean, they're not going to take something, but they do have, for example, take bouillon. And that's something that people commonly eat. So could you ever have bouillon with something like this? Well, one of the problems with bouillon is you boil things for a long time and it will destroy almost anything you put in, you know, these micronutrients. So one of the questions that we started talking about is, could you come up with, again, a little coating that you could take any nutrient in, and that if you put it in boiling water for two hours, nothing happens. No change in color, taste, no destruction of it. But when you eat it, it'll all come out. Now, that might seem, how could you do that? But actually you can. And what we did is we actually, I had some theory. There are some polymers, some are even FDA approved that you can, that are, because of their groups. If they have one charge, let's say a neutral pH, they're insoluble. So in other words, they'll form. But when you go to acid pH, the charge has changed essentially, and they'll dissolve. So what we did is we actually, so I had that idea and we actually looked at maybe over 50 to a hundred different materials. But what was exciting, and when you look at this is what you see is just going over, I'm just going to look at this, 'cause it's hard doing this without glasses. But what you can see when you look at this is an in vitro experiment. Now we've done lots of even human experiments, but what you see is when you look at this, there's 11 different ones. And in each case, what happens is if you put them in stomach acid, those are the top curves. Every single one comes out. But if you put it at neutral pH, nothing comes out. And if you boil it, nothing comes out. So this was in vitro, then we did it in small animals. This was led by Ana Jaklenec in our lab. And then people, and then, you know, we actually created with the foundation, I don't want to call it a nonprofit, it's, I guess, kind of a B Corp, we call it Particles for Humanity. And they've worked with different manufacturers. They got it actually approved by the World Health Organization equivalent of the FDA and now manufactured. And the hope is that it will get introduced into Africa either later this year or early next year. But, you know, a lot of it's politics where you have to talk to governments and stuff like that. But the Gates Foundation is helpful on that too. So we're looking at not just- that's just for vitamin A. Another big issue is adherence. This is the US data, but people don't take drugs. So that's nutrition for drugs. People don't do a very good job, even in our country. This was from Annals of Internal Medicine and written in The New York Times. But the lack of adherence causes 125,000 deaths and 10% of hospitalizations. This is in the US World Health Organization actually shows considerably bigger numbers worldwide. So some of the things we've done with Gio Traverso, another fellow of ours, now a professor at MIT, is come up with pills that you could swallow that could last for an entire course of treatment, like a pill, and some of these are for treating malaria and other things. So that patient could just take something once. But what you can do is we came up with ways, and I could go into the science where it'll last for the entire- the pill, which is the easiest thing to get somebody to adhere to, will last for a week. Or we've done that will last for a month. There's actually birth control ones that are being developed or, however, maybe even a year. And that's all oral. And I'm happy to go over how we did it. But we also thought you could do some things for vaccines. Because people don't come back for a second injection either. And this was way before COVID. And so actually we invented a new, you know, people are all familiar with, you know, 3D printing. So we actually came up... a lot of it is kind of nanotechnology. This actually even involved PICO technology that we came up with a new way of making systems that could deliver drugs at pretty much any time. So our idea is you'd make a cocktail, that maybe you could make one that will dissolve. And you'll have these little kind of boxes. They're very, very tiny, and they're like little eggshells. But we could make those eggshells. We could make a polymer that will dissolve into very safe things like water and CO2, at almost any time you want. And the way you can do that is take polylactic acid, that's the material polylactic glycolic acid. It's FDA approved, it's used in sutures and drug delivery systems. But by changing the molecular weight, changing the ratio of lactic to glycolic acid, adding esters or acids or adding buffers like calcium carbonate, you can make them dissolve at any time. So here I'll let you see. You give one injection, but you get 11 bursts. And so this is also something that we hope to make available. So with the foundation, we've started 25 different clinical trials at different stages. We've done this through, you know, different mechanisms and so some are companies that we've started, some are with the foundation, some are at hospitals. So these are some of the things that we've tried to do. I think what I'll do is stop here, but trying to give a flavor of some of how I got started, a few roadblocks that I ran into, and maybe more than just a few, but also, you know, what you can try to do with science and engineering and chemistry. So let me stop here and do the fireside chat.
Joan Reede 35:11 ↗
Thank you. We're going to move to the fireside chat. I'm hoping that you're thinking of questions, comments from what has been said, but we're going to move to the chat. We're going to move over to these seats. One of the things that struck me in this is the capacity to hear just quit. It's impossible. It won't work, can't be done, and you stay with it. What is it that enabled you to keep pursuing?
Robert Langer 35:52 ↗
Yeah, I think a couple things. I mean, one, I do think I had a great role model with Dr. Folkman. I got to see firsthand, people may not realize when somebody looks back at it today, you know, what it might've been like then. But he would get widely criticized for those ideas. And so I certainly got to, and yet I could also see certainly with my own eyes, and you can see those pictures that his vision was correct. I saw it with my own eyes too, you know, that even though people were saying it's impossible, I mean, it's not impossible. So, and also I was fortunate I had some good friends who were supportive, and like I say, I had him as a role model. I mean, but it's not very pleasant. I mean, you know, I was depressed for a year or two and that wasn't so good either. But you get through it.
Joan Reede 36:55 ↗
You know what, but what I'm hearing also is it wasn't just a matter of no, no, no, and it's like you have this thick wall around you. It impacted you. You were able to still go forward. And I think about some of the challenges and things I see today, it's like you can get discouraged. But you keep going.
Robert Langer 37:15 ↗
Yeah, you know, I actually, maybe I will show, I did bring another couple slides here. This is, I'll just show you one that I tell my students, and this was from one of my students who was a professor at Purdue. And she got her grant turned down. And I had no idea she even wrote this, but I would tell her that. And so that's Iune, and she, and what I basically said to her is, anyone can do great when things go well, it's what you do when things are not in your favor that makes a difference. So I think that, I mean, of course these things are easier to say, they're much harder to do. But you know, you keep trying.
Joan Reede 38:01 ↗
The other part I'm struck by is you talked about several people from Judah Folkman to other individuals that you partner with. Can you talk a little bit about this journey? 'Cause it didn't feel like you did everything by yourself.
Robert Langer 38:16 ↗
Oh, hardly, yeah. Well, I mean, I think I've mentioned a number of people and, I mean, the biggest, of course, has been my students and postdocs. They're, you know, they, I mean they've been terrific. And really when people ask me what I'm proudest of, I usually say how well they've done. And I mean, I think I must have something like 10 people who are professors at Harvard and 11 at Stanford, and I think 10 at MIT. I mean, you know, they're professors all over the world. A lot of 'em have started companies. And so I've been very lucky to have had just incredible students. I've also had people at, you know, in the business community, Mark Levin's here. And he's certainly been, you know, I worked, there's quite a few investors, Mark, Terry McGuire, Noubar Afeyan. And they, I've done, I've had a lot of help and support whenever we've tried to start companies. Now, I think, I mean, of course I've probably had over a thousand people come through my lab, but I say probably five or 10 are investor types and venture capitalists. And, you know, they've also been very helpful. So, I think anytime you try to do any of these things, it's a giant team effort. And so, you know, kind of, so a lot of these things start out as a project in the lab. And sometimes it doesn't work out. I mean, but you do the best you can, and sometimes it does work out, and you want to do what you can to not only write, to me, a scientific paper, but get it out to the world. And so I think it takes multiple elements. It takes scientists. If you're going to have a successful company, it takes, I mean, all kinds of things. You're going to need people who are good business people who are good clinical people, who are good manufacturing people, I mean, and on and on. So it's a giant team effort. And so I think I've been very fortunate to work with great people.
Joan Reede 40:32 ↗
As you say that, I just think, I think in terms of systems, and you talk about the scientists, the clinician, the business people, the attorneys, the policy people, and all these different spaces who enable advances to get from the lab to people. At the same time, we tend to silo some of our work that we're doing, and without this understanding of a larger system and the connections across it, how did those early experiences of rejection, how did, or have they influenced you? Judah Folkman said, I'll take you, even though you don't look like the model of what someone's looking for. So there were people who turned away because you didn't fit their model. When you're selecting people, the mentor to advise, to bring in your lab and move forward, do you have a preset model of what they should be?
Robert Langer 41:29 ↗
Yeah, well, my preset model is that they should be great, and I've often, I think Judah Folkman, I mean, I've certainly, not that I'm great, but I think he actually didn't want a preset model. He felt, he said to me, people had tried to solve problems like that for years and they hadn't succeeded. So try somebody with a very different background. For me, I mean, just to give examples of people that I've hired that have, you know, wouldn't fit a very good model for an engineer. I'll just give you a couple examples, but they don't necessarily have what you'd expect for the right background for the right grant. A really good example is a fellow named Gio Traverso. Gio got his PhD with Bert Vogelstein, who's a top molecular biologist, but not an engineer. He's at Johns Hopkins. He's a gastroenterologist. He came to Mass General, I think, to do a fellowship, and he decided he'd like to try doing oral, you know, to look at drug delivery. So he came, worked in our lab for a number of years and he really, you know, he had actually a Harvard faculty appointment, but he really liked the, you know, like when I talked about those pills that last for a long time. He's done all kinds of things. He's made pills that can deliver large molecules too. But at any rate, so he came, and he liked,
Even though he is a molecular biologist, the mechanical engineering department at MIT a few years ago had an opening that, and it is, again, not to brag about it, but they're the number one mechanical engineering department in the world. They, I think, 400 people applied and they chose him. And now he's got, you know, he's a full professor. He has, I mean, I think he probably has one of the largest NIH grants in the country, a $65 million or $75 million grant. I think he's got a couple of these, you know, it's a, but he had, you know, he is really, I think he has like about 70 papers in Science or Nature, and he is still a really young guy. But I've had quite a few people like that here, you know, Dan Kahane is at Children's Hospital and he had a very different background. And Dan Anderson was a molecular biologist, came to our lab, he's a professor of chemical engineering. He started CRISPR Therapeutics and other companies. I mean, but I probably go for unusual people too.
Joan Reede 44:08 ↗
I'm hearing that, but I'm also hearing it is that maybe for individuals we self-censor where we think we can go, or where we belong, and maybe sort of broadening our thoughts about where we can do our work, our best work, or who we work with in those spaces.
Robert Langer 44:26 ↗
I think it is good to broaden your thoughts. I think the problem is the people that are hiring you usually don't, I mean, that was certainly what I experienced. You know, I think if I had done chemistry curriculum development, I would've done okay at City College. But, you know, the problem is, I don't know. I mean, but I agree with you. I think, I actually think doing things that are different, you grow from doing that, but a lot of times it's not easy to get the chance.
Joan Reede 44:55 ↗
Well, I think there is also a piece of this that you keep hearing: focus, focus, focus.
Robert Langer 45:00 ↗
Well, that I think that's important too. I mean, I think you know, it's really when we do things in the lab, or if you do things in a company, if you don't focus, you're not gonna get anywhere. So you, I think it's, I do feel you have to do that. I mean, I think that when somebody comes into the lab, I just say, well, you know, they get a project. If they are making good progress on it, then sometimes it's worth looking at other aspects or other projects. But I do agree with, you know, I remember I had a student once and he was actually brilliant and every day he'd come in with a different idea. And I said, you know, but you've gotta finish the last one.
Joan Reede 45:42 ↗
Stick with something.
Robert Langer 45:43 ↗
Well, yeah, but I mean, it's important that you—
Joan Reede 45:47 ↗
I think what I'm hearing, and part of this though, is that focus is critical, but not so focused that you don't see out of your lane and don't see some connections and aren't willing to step into other spaces.
Robert Langer 46:00 ↗
Yeah, well, I don't feel that they're mutually exclusive though. I think that you can, a lot of things that we talk about, I mean, today are what we think about as a convergence. You know, Phil Sharp and I wrote an article on that in the journal Science 15 years ago. And actually the point I sometimes make on convergence, that's bringing many disciplines together. But what happens, I think, if you look at most universities, for example, you know, there's a building for math, there's a building for English, there's a building for chemical engineering, a different building for mechanical engineering. But I think that maybe robs people of the opportunity to mix with people that have very different backgrounds than their own. And so I'm not trying to say that you shouldn't have some of those buildings, but maybe, you know, that are monodepartmental. But it may be good to have institutes and, you know, some places, MIT is one of them, Stanford, Georgia Tech, you know, they have buildings that do bring people together.
Joan Reede 47:03 ↗
Bring people together, or I think about what we're trying to do with portals of crossing disciplines, crossing institutions in a space, to build that different kind of community. Can you, 'cause there's been so many changes, can you speak a little bit about what you think are some of the most impactful changes that you've seen in science over your career? And you've talked about the drug delivery systems, etcetera. Are there other big areas that you think are of change in science?
Robert Langer 47:35 ↗
Well, I think things have changed enormously. I think, you know, now, I mean, the latest thing everybody talks about is artificial intelligence. And by the way, that existed, you know, over 55 years ago too. But it's certainly, you know, computation power is so much increase that you can, you know, do things faster and so forth. So that's probably, if somebody talks about in 2026, you know, that's certainly one that would come, you know, very high on your list. But, you know, there's so much difference in equipment that there's so many discoveries that people have made. And, you know, things like gene therapy that might have only been a dream. And I mean all aspects of it from, you know, from gene editing to siRNA to mRNA, I mean, none of those things were even on the horizon. Maybe a couple of people had thought about it, but, you know, I think there's so many things. And then high throughput testing, I mean, you know, there's again, robotics. I mean there are so many things that you can do. And I mean, it's pretty unlimited. I'm not sure where to start. You can just look at all of the work that has been done on so many things.
Joan Reede 48:53 ↗
I mean, it's sort of this exciting open space. It's not just one path.
Robert Langer 48:57 ↗
Yeah, that's well said, yeah.
Joan Reede 48:59 ↗
And I'm gonna turn this over, but there's a piece of this that just really struck me in terms of the kind of work I do. And a lot of work I do is around workforce development, career development, talent identification, leadership development. And I'm struck by the early work you did as a student in terms of developing curriculum for school. And I know you've spoken before some students in one of the programs that we had here. Can you talk a little bit about your thoughts on how we bring individuals into science or who's left out, who's included, and is it important for us to be thinking about that?
Robert Langer 49:41 ↗
I think it's important to be thinking about it. I think the biggest thing that's important is getting kids excited at a young age. I mean, grammar school, high school. So I think it's a really important thing when I was doing that with that school. I mean the two things I noticed were, or that I tried to think about was, how do you make it fun and how do you make it relevant? And I feel like those two things are not done nearly enough with a lot of curriculum. And even when I remember having to teach thermodynamics at MIT, which was an interesting experience 'cause most of what you teach is 200 years old, which is, you know, like steam tables and stuff. And you try to figure out how do you make that relevant, and how do you make that fun? But I think you can come up with things, and so I try to do that for any of the things that I would teach, to try to bring those two aspects in. But I think trying to make education, you know, exciting, try to make science exciting and try to make it valued. I think it's a very important thing, and it's at all levels. I mean, I'm talking about education. I think, you know, there's a saying that a society gets what it celebrates. And, you know, I was talking with somebody from China yesterday, and he was saying, you know, I was visiting MIT and he was saying, you know, that he was talking about how in America somebody runs for student council and they're gonna be president of the student council in high school, you know, they're gonna be an athlete or a cheerleader or something like that. He said, you know, in China, it's the person who's number one in math and that, you know, that's what they look for. And you see that, you know, like the media glorifies athletes and actresses and actors and, you know, science is, you know, not front and center in a lot of things.
Joan Reede 51:54 ↗
So as you say that to me, are there ways for us to start to celebrate and bring it forward in terms of showing the joy? And I listen to you and I hear joy and excitement as you talk about being 77, and I'm thinking you could be 20 in this room and have the same amount of joy and excitement. It's just this energy.
Robert Langer 52:11 ↗
Yeah, I would like to figure out a way to—
Joan Reede 52:14 ↗
Do that. (laughs) To package that. I wanna open this up for other questions from here. On your tables, there's microphones, if you press the button. You're free. I love this. I love these moments of, do I say anything? Do I ask anything?
Attendee 1 52:39 ↗
Working? Well, if you could hear me, hi. Hi, Professor. Thank you. You've been a huge inspiration for me personally to get into the field of biomedical engineering in the first place. You mentioned Gio Traverso, and I need to double check this myself, but I think, you know, one of his PhD students is my PhD supervisor. So I think we're somewhere connected in this academic family line. But I was wondering if you could comment on his and your work together on this.
Robert Langer 53:11 ↗
Who was the—I had trouble hearing the name.
Attendee 1 53:14 ↗
My supervisor Khalil Ramadi. He was at MIT as well, and he came over to NYU.
Robert Langer 53:21 ↗
I say, yeah. I've met him, but I don't think I've worked with him.
Attendee 1 53:27 ↗
Yeah, no. Through you, I guess through Gio.
Robert Langer 53:31 ↗
Worked with Gio?
Attendee 1 53:31 ↗
Gio, yeah.
Robert Langer 53:32 ↗
Yeah, well—
Attendee 1 53:34 ↗
And I was just wondering if you could comment on that retention time with the pills and the oral?
Robert Langer 53:38 ↗
Oh, how that works?
Attendee 1 53:39 ↗
Yeah, yeah.
Robert Langer 53:40 ↗
Yeah, well, so you could make, so the idea, I mean, using some of the things that I mentioned, it's pretty easy if you inject something to make it last for... If you make it last for a week or a month or a year, I mean, you can actually make things last for five years if you do certain things, but that's injection. The problem when you swallow it is there's usually about a 24-hour transit time and then it's out in the feces. So what we did is Gio, and now I remember he worked with Mike Cima too, if I remember, so basically what we did is you could make things in certain shapes, right? And develop what I'll call shape memory materials. So let's say I made something with a shape like this. There are other shapes, but let's say it's a shape like this. So you could squish it up and put it in a little capsule. I might even have one in my bag. I'd have to check. So you take one of these things with a certain shape and you squish it up and you put it in a capsule. So at the end of the day, you just take a gelatin capsule, which is pretty simple. But this is all squished up. Now the gelatin capsule dissolves in your stomach acid pH, so this thing will pop out. But if it has shape memory, it pops out in a shape that's so big, it can't pass through the pylorus, it'll just stay in your stomach, but so open that food can pass, 'cause you don't want it to block things. So you come up with a shape. We have different shapes that we design and then you have a part of it that is degradable. I probably even have some in the— you have a part of it that's degradable. We also had one— anyhow, so the part that's degradable, you can tune, you can make it dissolve in a week, in a month or a year, and it keeps sitting there releasing, releasing, releasing. But when that part breaks, then everything goes out and it just goes out, and it'll dissolve either, you know, or it'll go out in the feces, let's say. And ultimately, again, it would go into harmless molecules. I don't know if I explained it, but—
Joan Reede 55:59 ↗
Yeah.
Robert Langer 56:00 ↗
It's really controlling, building on two things. One, delivery principles, like we've worked on for years, but then secondly, building on that shape, getting the right shape, memory properties, which there's some ways you can do that.
Attendee 2 56:21 ↗
Thank you for your words. I'm curious when working in your labs, like in order to have that type of innovation, there has to be so much experimentation and people not being afraid of being wrong or challenging ideas. I'm curious to learn, like, what processes do you set up in your lab to allow for all these ideas to emerge where people are comfortable with sharing an opinion or a minority opinion? You may be like, yeah, go for it. Like, are there any type of structure that you have in place that allow for that to happen?
Robert Langer 56:48 ↗
Well, that's a really good question. I don't think it's a structure. I think it's like a frame of mind, you know, like I never really liked it when people told me like, my ideas were wrong, but sometimes ideas are wrong or they're gonna be very difficult. So, you know, one of the other things I thought that was very good for me when I worked in Dr. Folkman's lab, I always said that he used what I call positive reinforcement. You know, that meaning that you could look on the negative side of something, but you can also look on the positive side. And I mean, I think like it, and you can also let people know it's okay to fail, you know, I think that people make mistakes all the time. So I really think it's a frame of mind. I think it's also examples. I mean, people see, you know, I mean, I've certainly had my failures. Lots of people who are older, you know, are there, and the younger people see them and, you know, so I really think it's just an attitude rather than a structure. But I think Dr. Folkman had that structure, and I mean, I've seen other places have it, but it's really being willing to try things, know that they're not necessarily gonna work right the first time or even the hundredth time. But if you feel it's important, and again, if somebody has to do a thesis, you don't want them to spin their wheels, you want them to get something, but, you know, I think it's okay to ask for help. So it's more just trying to do things that you feel are important and keep trying. I wish I could say some magic words that we do, but I think there's structure, but don't think I have that.

44 more exchanges in this transcript

Sign in free to read the rest of this interview. No card required.

Sign in to read the full transcript

Cite this transcript

APA, MLA, BibTeX
APA

Langer, R. (2026, May 4). Portals to Excellence and Impact Presentation and Fireside Chat with Dr. Bob Langer [Interview transcript]. HMS OCCE. CEOInterviews.AI. https://ceointerviews.ai/interview/3241636/

MLA

Robert Langer. "Portals to Excellence and Impact Presentation and Fireside Chat with Dr. Bob Langer." HMS OCCE, 4 May. 2026. Transcript, CEOInterviews.AI, https://ceointerviews.ai/interview/3241636/.

BibTeX
@misc{langer2026_3241636,
  author       = {Robert Langer},
  title        = {Portals to Excellence and Impact Presentation and Fireside Chat with Dr. Bob Langer},
  howpublished = {Interview transcript, HMS OCCE. CEOInterviews.AI},
  year         = {2026},
  month        = {may},
  url          = {https://ceointerviews.ai/interview/3241636/},
  note         = {Speaker-attributed transcript with timestamps}
}